ipragliflozin
Trade name: sublet
Small moleculeexperimental
Ipragliflozin is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019. — Wikipedia
Clinical trial activity
51 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
24
Phase 3
19
Phase 4
5
Earliest trial started Nov 1, 2006 (NCT01288885)
Timeline
Indications
Approved for
Mechanism of action
- Sodium/glucose cotransporter 2INHIBITOR
SLC5A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O- Mol. weight
- 404.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaIpragliflozin ↗
- ChEMBLCHEMBL2018096 ↗
Also known as
- asp1941
- asp1941
- asp1941
- ipragliflozin
- ipragliflozin
- ipragliflozin
- ipragliflozin
- ipragliflozin
- ipragliflozin
- ipragliflozin l-proline
- ipragliflozin l-proline
- suglat
- suglat
- suglat
- suglat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03076112 | Phase 3 | Apr 25, 2017 | Astellas, Seoul National University |
| NCT02897219 | Phase 3 | Aug 29, 2016 | Astellas |
| NCT02847091 | Phase 4 | Jul 29, 2016 | Astellas |
| NCT02791035 | Phase 4 | Jun 1, 2016 | Astellas, Kyung Hee University, Sungkyunkwan University, University of Ulsan, Yonsei University |
| NCT02794792 | Phase 3 | May 16, 2016 | Astellas |
| NCT02875821 | Phase 4 | Apr 26, 2016 | Yonsei University |
| NCT02577016 | Phase 3 | Nov 1, 2015 | Merck |
| NCT02577003 | Phase 3 | Nov 1, 2015 | Merck |
| NCT02564211 | Phase 3 | Oct 1, 2015 | Merck |
| NCT02529449 | Phase 2 | Sep 1, 2015 | Astellas |
| NCT02452632 | Phase 3 | Jul 1, 2015 | Astellas |
| NCT02291874 | Phase 4 | Oct 1, 2014 | Astellas |
| NCT02175784 | Phase 4 | Mar 1, 2014 | Astellas |
| NCT01972880 | Phase 1 | Sep 1, 2013 | Astellas |
| NCT01672762 | Phase 3 | Jun 1, 2012 | Astellas |
| NCT01514838 | Phase 3 | Jan 1, 2012 | Astellas |
| NCT01505426 | Phase 3 | Nov 1, 2011 | Astellas |
| NCT01611363 | Phase 1 | Oct 1, 2011 | Astellas |
| NCT01611415 | Phase 1 | Jul 1, 2011 | Astellas |
| NCT01611428 | Phase 1 | Jun 1, 2011 | Astellas |
Showing 20 of 51 trials
Page 1 / 3
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 47 | 45 | 4 | 2006 |
| Merck | For profit | 3 | 3 | 1 | 2015 |
| Yonsei University | Academic/Hospital | 2 | 1 | 1 | 2016 |
| Kyung Hee University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2016 |
7 organizations
Page 1 / 1